Who Paid My Doc
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm
Research payments
$4,776,738
Through program year 2024, $4,776,738 in research payments was reported against A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, across 505 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,357,649 | 98 |
| 2023 | Research | $53,577 | 8 |
| 2022 | Research | $985,814 | 137 |
| 2021 | Research | $2,379,698 | 262 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jose Diaz The Villages, FL Named on 35 payments
- Jeffrey Tillinghast Saint Louis, MO Named on 30 payments
- Shaila Gogate Frisco, CO Named on 28 payments
- Vivek Iyer Rochester, MN Named on 21 payments
- Aaron Milstone Franklin, TN Named on 19 payments
- Karl Sitz Little Rock, AR Named on 16 payments
- Gary Gross Dallas, TX Named on 15 payments
- Benjamin Bregman Winston Salem, NC Named on 14 payments
- Iftikhar Hussain Tulsa, OK Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.